Centaurus Financial Inc. lifted its holdings in Danaher Co. (NYSE:DHR - Free Report) by 47.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,208 shares of the conglomerate's stock after purchasing an additional 4,276 shares during the period. Centaurus Financial Inc.'s holdings in Danaher were worth $3,032,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in shares of Danaher by 11.6% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate's stock worth $4,874,000 after purchasing an additional 2,202 shares during the period. FAS Wealth Partners Inc. lifted its stake in shares of Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock worth $2,203,000 after purchasing an additional 1,639 shares during the period. Generate Investment Management Ltd bought a new position in shares of Danaher in the 4th quarter worth approximately $8,044,000. Compass Capital Management Inc. lifted its stake in shares of Danaher by 4.8% in the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate's stock worth $54,615,000 after purchasing an additional 10,994 shares during the period. Finally, Channing Global Advisors LLC increased its holdings in Danaher by 42.8% in the 4th quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate's stock worth $1,301,000 after acquiring an additional 1,698 shares in the last quarter. Institutional investors own 79.05% of the company's stock.
Danaher Price Performance
Shares of DHR stock traded down $0.93 on Friday, reaching $189.54. The company's stock had a trading volume of 6,514,078 shares, compared to its average volume of 3,485,177. The stock's fifty day simple moving average is $192.72 and its 200-day simple moving average is $213.78. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $135.65 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.66 and a beta of 0.80.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. Danaher had a net margin of 16.33% and a return on equity of 10.82%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.68%. Danaher's dividend payout ratio (DPR) is presently 24.85%.
Analyst Ratings Changes
Several research firms recently issued reports on DHR. Royal Bank of Canada reissued an "outperform" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. UBS Group reduced their target price on shares of Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a report on Thursday, January 30th. Barclays increased their target price on shares of Danaher from $205.00 to $215.00 and gave the stock an "overweight" rating in a report on Tuesday, April 22nd. Finally, HSBC reduced their target price on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $263.24.
Get Our Latest Report on DHR
Insider Activity at Danaher
In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
